Clinical Trial NCT05133531
Trial
Regeneron – R3918-PNH-2021 2050 2021- ACCESS-1 (NCT05133531)
Clinical trial ID
NCT05133531
Drug name
Pozelimab and Pozelimab and Cemdisiran
Company:
Regeneron
Drug trade name
---
Clinicaltrials.gov
Learn more
Phase of study
3
Current status
Recruiting
Start
8/2022
Substance
Monoclonal antibody
Research question
Versus ravulizumab, treatment naive or not recently inhibitor treated
Delivery method of drug
i.v./then s.c.
Frequency
---
Clinical trial locations
Singapore South Korea Taiwan USA